Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis

Am J Hematol. 2021 Apr 1;96(4):E103-E105. doi: 10.1002/ajh.26091. Epub 2021 Jan 28.

Authors

Philip S Boonstra¹, Asra Ahmed², Samuel A Merrill³, Ryan A Wilcox²

Affiliations

¹ Department of Biostatistics and the Center for Cancer Biostatistics, University of Michigan, Ann Arbor, Michigan.
² Division of Hematology/Medical Oncology, Department of Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, Michigan.
³ The Section of Hematology, Department of Medicine, West Virginia University, Morgantown, West Virginia.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
COVID-19
Clinical Trials as Topic / statistics & numerical data
Cytokine Release Syndrome / drug therapy
Cytokine Release Syndrome / etiology
Female
Humans
Lymphohistiocytosis, Hemophagocytic / complications
Lymphohistiocytosis, Hemophagocytic / drug therapy*
Male
Nitriles
Pilot Projects
Progression-Free Survival
Prospective Studies
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use*
Pyrazoles / adverse effects
Pyrazoles / therapeutic use*
Pyrimidines
Recurrence
Treatment Outcome

Substances

Nitriles
Protein Kinase Inhibitors
Pyrazoles
Pyrimidines
ruxolitinib

Grants and funding